REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Wall
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F
Form 144 REGENERON PHARMACEUTICAL Filed by: Pitofsky Jason
Form 13F-HR REGENERON PHARMACEUTICAL For: Dec 31
Form 10-K REGENERON PHARMACEUTICAL For: Dec 31
Form 8-K REGENERON PHARMACEUTICAL For: Jan 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.